Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
RNAC 
Cartesian Therapeutics Inc. (RNAC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: RNAC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.17
1 Year Target Price $36.17
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -54.28% | Avg. Invested days 15 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 351.42M USD | Price to earnings Ratio 2.54 | 1Y Target Price 36.17 |
Price to earnings Ratio 2.54 | 1Y Target Price 36.17 | ||
Volume (30-day avg) 8 | Beta 0.83 | 52 Weeks Range 8.46 - 26.50 | Updated Date 07/11/2025 |
52 Weeks Range 8.46 - 26.50 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.33 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -112.11% | Operating Margin (TTM) -1989.91% |
Management Effectiveness
Return on Assets (TTM) -7.55% | Return on Equity (TTM) -7029.26% |
Valuation
Trailing PE 2.54 | Forward PE 25.45 | Enterprise Value 191022587 | Price to Sales(TTM) 10.28 |
Enterprise Value 191022587 | Price to Sales(TTM) 10.28 | ||
Enterprise Value to Revenue 5.59 | Enterprise Value to EBITDA -1.17 | Shares Outstanding 25954300 | Shares Floating 9342507 |
Shares Outstanding 25954300 | Shares Floating 9342507 | ||
Percent Insiders 59.96 | Percent Institutions 25.63 |
Upturn AI SWOT
Cartesian Therapeutics Inc.
Company Overview
History and Background
Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company pioneering RNA cell therapy for autoimmune diseases. The company's platform engineers cells to express RNA, offering potential for controlled and transient therapeutic effects.
Core Business Areas
- RNA-Engineered Cell Therapy: Developing and commercializing RNA-engineered cell therapies for autoimmune diseases.
Leadership and Structure
Details regarding the leadership team and structure are publicly available on the company's website and SEC filings. Please note: Cartesian Therapeutics had a public offering in 2023
Top Products and Market Share
Key Offerings
- Descartes-08 (autologous RNA-engineered CAR-T cell therapy targeting B-cell maturation antigen (BCMA)): This is the lead product candidate in clinical development for multiple myeloma. Cartesian is focusing on autoimmune indications with a Phase 2b study in myasthenia gravis. Competitors include companies developing CAR-T therapies for hematological malignancies.
- Descartes-33 (autologous RNA-engineered CAR-T cell therapy targeting CD33): Under development for acute myeloid leukemia (AML). Descartes-33 expresses a CAR that directs T cells to kill CD33+ cells. Competitors include other companies pursuing CAR-T therapies for AML.
- Descartes-25 (autologous RNA-engineered CAR-T cell therapy targeting a novel target on prostate cancer cells): Under development for advanced prostate cancer. Competitors include companies developing other CAR-T therapies and traditional cancer treatments for prostate cancer.
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in genetic engineering and the increasing prevalence of chronic diseases. Competition is intense, with numerous companies developing innovative therapies.
Positioning
Cartesian Therapeutics is positioned as a pioneer in RNA cell therapy, offering a differentiated approach compared to traditional gene therapies. The company focuses on autoimmune diseases and cancer.
Total Addressable Market (TAM)
The TAM for cell therapies in autoimmune diseases and cancer is substantial, estimated to be in the tens of billions of dollars. Cartesian is aiming to capture a significant share of this market through its innovative RNA-engineered cell therapy platform. Details on exact numbers can be seen in their investor relations presentations.
Upturn SWOT Analysis
Strengths
- Innovative RNA-engineered cell therapy platform
- Focus on autoimmune diseases with high unmet need
- Strong intellectual property portfolio
- Experienced management team
Weaknesses
- Limited clinical data compared to established cell therapy companies
- High development costs associated with cell therapy
- Manufacturing complexity
- Dependency on regulatory approvals
Opportunities
- Expanding pipeline to address additional autoimmune diseases and cancers
- Partnering with larger pharmaceutical companies
- Securing regulatory approvals for lead product candidates
- Advancing manufacturing capabilities
Threats
- Competition from established cell therapy companies
- Adverse clinical trial results
- Regulatory hurdles
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- CRIS
- EDIT
- BEAM
Competitive Landscape
Cartesian's RNA-engineered cell therapy platform provides a differentiated approach. While other firms may have more market share currently. Cartesian has a unique platform.
Growth Trajectory and Initiatives
Historical Growth: Cartesian's growth has been driven by the advancement of its pipeline and platform. Refer to company filings for exact numbers.
Future Projections: Future growth depends on clinical trial success, regulatory approvals, and commercialization efforts. Analyst estimates are available from various financial sources.
Recent Initiatives: Recent initiatives include advancing lead product candidates through clinical trials and expanding its pipeline. Please review company filings for the most current data.
Summary
Cartesian Therapeutics is an emerging player in the cell therapy space, utilizing a unique RNA-based approach. Its focus on autoimmune diseases provides a niche in a growing market. Success hinges on clinical trial outcomes and regulatory approvals. The company faces competition from established players and the high costs of drug development.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Cartesian Therapeutics' SEC filings (e.g., 10-K, 10-Q)
- Cartesian Therapeutics' investor relations materials
- Analyst reports from financial institutions
- Industry reports on the cell therapy market
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cartesian Therapeutics Inc.
Exchange NASDAQ | Headquaters Frederick, MD, United States | ||
IPO Launch date 2016-06-22 | President, CEO & Director Dr. Carsten Brunn Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 66 | |
Full time employees 66 | |||
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous anti-BCMA mRNA CAR-T to treat autoimmune diseases, such as relapsed/refractory multiple myeloma. The company is headquartered in Frederick, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.